[ Price : $8.95]
Akin Gump attorneys highlight major issues in the PDUFA 8 commitment letter that is now open for public comment.[ Price : $8.95]
MasterControl issues its 2026 life sciences regulatory readiness playbook demonstrating the significant ways in which the FDA Qual...[ Price : $8.95]
The U.S. Court of Appeals for the Fifth Circuit upholds FDAs decision to remove tirzepatide from the agencys drug shortage list, a...[ Price : $8.95]
Reed Smith attorney James Beck says courts so far have rejected all arguments citing the Supreme Courts Loper Bright decision as a...[ Price : $8.95]
Celcuity files a supplemental NDA for Revtorpyk (gedatolisib) for treating certain patients with hormone receptor positive, human ...[ Price : $8.95]
FDA approves Revolution Medicines Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer.[ Price : $8.95]
CNBC reports that HHS plans to appoint two new FDA deputy commissioners in hopes of exerting more influence over the agency.[ Price : $8.95]
FDA says the Boston Scientific recall of its ENROUTE Transcarotid Neuroprotection System is Class 1.